6:12 PM
 | 
Aug 01, 2014
 |  BC Extra  |  Clinical News

Biota's laninamivir octanoate misses in Phase II influenza

Biota Pharmaceuticals Inc. (NASDAQ:BOTA) said laninamivir octanoate delivered via TwinCaps dry-powder inhaler missed the primary endpoint of improving median time to alleviation of influenza symptoms vs. placebo in the intent-to-treat (ITT) population of the Phase II IGLOO trial to treat influenza infection. The double-blind trial...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >